Vaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response
Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study
Nasal spray cuts COVID-19 growth, study shows
Biomedical Translation Bridge Program grants $1m to develop a drug treatment for obesity-related health conditions
OncoRes Medical awarded prestigious research funding
Innovative type two diabetes treatment scores $29m
$29M investment to develop new treatment for type 2 diabetes
Vaxxas announces that MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate
Harro Höfliger and Vaxxas Announce Alliance to Develop Industrial‐scale Aseptic Processing Line for Vaccine Products Based on Vaxxas’ High Density Microarray Patch (HD‐MAP)
Nation faces ‘generational loss’ of biotechs warning
Urgent COVID-19 response package needed to support and protect $170b life sciences sector
Bill Ferris, pioneer venture capitalist, appointed Chair of the MRCF
Vaxxas High-Density Microarray Patch to Efficiently Deliver Vaccines Directly to Skin
Vaxxas Awarded US$5 million Grant for Clinical Study of Measles and Rubella Vaccination
Multi-million-dollar mission to tackle major global health challenges
MRCF establishes life science incubator to boost NZ startup successes
QUE Oncology recruiting Sydney breast cancer patients experiencing hot flushes & night sweats
$14m invested in University of Melbourne spin-out to create vaccine for periodontal gum disease
Perth tech joint-winner in global finals for international start-up competition
Q-Sera’s innovative blood clotting technology granted patent in US
QUE Oncology launches Phase II trials in New Zealand
QUE Oncology Appoints Dr. Julie Cherrington and Elizabeth Cermak to Board of Directors
PolyActiva completes recruitment in key Phase I glaucoma implant safety study.
Morphoseq™ at ‘Sequencing, Finishing and Analysis in the Future’ meeting, USA
Longas Launches, Unveiling Morphoseq™ Long Read DNA Sequencing Technology
Brandon Capital Partners launches new Medical Research Commercialisation Fund, seeks NZ institutional
QUE Oncology launches Phase II trials in the United States
MRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis
Aravax reveals positive Phase I trial results at world-leading allergy conference
Australian Phase II trial commences for potential world-first treatment of viral conjunctivitis
Perth tech takes out Australian start-up competition to join international finals
The WILD Program launches within the Victorian STEM sector, with first intake of 20 women
QUE Oncology launches Phase II trials
PolyActiva commences first Phase I clinical trial with potential to improve lives of millions
Paragen Bio launches in northern Queensland with $6 million investment
Azura Ophthalmics receives Series B funding to create treatment for major cause of Dry Eye Disease
MRCF announces largest investment to date by Biotechnology Translation Fund
Brandon Capital’s MRCF announces largest investment by Biotechnology Translation Fund
Okogen receives $13 Million Series A Funding for trials to treat the leading cause of eye infections
MRCF invests in San Diego ophthalmic biotech company, clinical trials to take place in Australia
Australian biotech company launched with AU$7m investment to develop therapies for treating obesity
Allergan to Acquire Elastagen to Access Next Generation Injectable Portfolio
New Zealand biomedical discovery set to revolutionise the global pain relief drug market
